MiceLab UdG

What MiceLab UdG does

MiceLab UdG (MICELAB), formally the Modeling, Identification and Control Engineering Laboratory, is research group GRCT0066 within the Institute of Informatics and Applications at the University of Girona, Spain. It operates at the intersection of control engineering, artificial intelligence, and biomedical research, with a primary focus on type 1 diabetes management and the development of next-generation artificial pancreas technologies. The lab comprises approximately 30 members — including faculty investigators, postdoctoral researchers, PhD candidates, and undergraduate interns — led by Prof. Josep Vehí Casellas, and is housed in the Edifici Narcís Monturiol at the University of Girona's Science and Technology Park.

The lab's technology stack spans advanced control algorithm development, high-fidelity digital twin and virtual patient simulation, AI-driven decision support systems, and wearable/IoT integration. Its productized offerings include Synulin AI — a synchronized smart insulin pen with integrated AI agent control, Virtual Human Twin simulation, and gamification, co-developed with Insulcloud; the Personal Digital Twin (PDT) using conditional deep generative models to optimize insulin therapy; and the Universal Concentrator (DT4) for hypoglycemia prevention. The research portfolio extends into adjacent biomedical domains via the European Commission PROMETEUS project (neonatal NICU metabolic monitoring, €3.7M) and the VaNeSA non-invasive vagus nerve stimulation platform. Two granted patents cover CGM enhancement (US 2022/0039698 A1) and insulin dose temporal distribution (AR099392A1). The lab's research output comprises over 700 publications, including 440 Q1 articles.

MiceLab generates revenue primarily through three streams: competitive research grants from the European Commission, AEI/MICIU, AGAUR, and other agencies (~€4.7M cumulative across ~200 funded projects); fee-for-service R&D consulting delivered under its TECNIO certification from ACCIÓ (Government of Catalonia); and the annual International Summer School on AI for Diabetes Management (€300/participant). Business engagement is sales-led and partnership-driven, targeting medical device developers (Dexcom, Insulcloud, SocialDiabetes), clinical research institutions (Hospital Dr. Josep Trueta, IDIBGI, EUSES), and academic collaborators (Imperial College London, University of Cambridge, Universitat Politècnica de València). The lab does not sell commercial software products and operates as a non-commercial academic unit under the University of Girona.

Name

MiceLab UdG

Legal name

Universitat de Girona (UdG) – MiceLab Research Group

Website

https://micelab.udg.edu

Company type

Private

Operating status

Operating

Headcount range

11–50 employees

Short description

MiceLab UdG is a University of Girona research group applying control engineering, AI, and biomedical modeling to type 1 diabetes management, developing digital twins, artificial pancreas algorithms, and AI-driven decision support tools for medical device and clinical partners.

Ownership category

akta.pro rank

Product category

Biomedical R&D and Digital Health Technology Transfer

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171), Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Central Laboratory & Clinical Trial Testing CROs (HLAGAAAE)

akta.pro secondary industry

Clinical Data Management, Biostatistics & Statistical Programming CROs (HLAGAAAF)

Keywords

• Biomedical research services
• Diabetes management algorithms
• Artificial pancreas technology
• Digital twin simulation
• Control engineering R&D

Headquarters

HQ city

Girona

HQ country

Spain

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Research Grants and Project Funding: MICELAB generates revenue primarily through competitive research grants from government agencies (MICIU, AEI, European Commission, AGAUR, Ministry of Digital Transformation) and international funding bodies. Total awarded funding is approximately €4,698,565.58. Funding supports specific R&D projects in AI for diabetes, digital health, and biomedical engineering.
2. Technology Transfer and R&D Consulting Services: As a TECNIO-certified technology developer, MICELAB offers fee-for-service R&D consulting to industry, hospitals, and research institutions. Services include algorithm development, simulation, clinical trial design, regulatory pathway consulting, and system integration — all billed through project-based contracts.
3. Education and Training Programs: Revenue generated from educational programs including the International Summer School on AI for Diabetes Management (€300 registration fee per participant). These programs cover academic coordination, daily lunches, coffee breaks, networking activities, and farewell dinner.

Pricing tiers

Go-to-market motion3 records

Distribution channels1 record

Marketing channels7 records

Core offering

MiceLab UdG is a university research group providing technology transfer and R&D consulting services at the intersection of control engineering, artificial intelligence, and biomedical research. The lab develops AI-driven algorithms, digital twins, closed-loop artificial pancreas systems, and decision support tools primarily for type 1 diabetes management, delivering these via project-based contracts to medical device companies, hospitals, and research institutions.

Product overview

MiceLab UdG is a research laboratory at the University of Girona offering technology transfer services and developing AI-powered products for diabetes management and biomedical applications. The portfolio includes core products like Synulin AI (smart insulin pen with AI agent control and Virtual Human Twin), Personal Digital Twin (PDT) for insulin therapy optimization, and Universal Concentrator (DT4) for hypoglycemia prevention. Services include Advanced Control Algorithm Development, Digital Twins and Virtual Patient Simulation, AI Decision Support Systems, Wearables/IoT Integration, and Collaborative R&D Consulting. The laboratory also conducts research projects including PROMETEUS (neonatal metabolic sensing) and VaNeSA (vagus nerve stimulation platform), all focused on bridging control engineering, AI, and biomedical research for chronic disease management.

Differentiator

Problem solved

Functional benefit

Products and services

• Advanced Control Algorithm Development
• Digital Twins and Virtual Patient Simulation
• Artificial Intelligence and Decision Support Systems
• Wearables and IoT Integration Services
• Collaborative R&D and Consulting
• Synulin AI Synchronized smart insulin pen system with integrated AI agent control, featuring Virtual Human Twin (VHT) simulation and gamification. Combines smart pen/Insulclock platform with AI coaching, real-time CGM monitoring, and behavior tracking for insulin-dependent diabetes management.
• Personal Digital Twin (PDT) AI-driven virtual human twin for optimizing insulin therapy in diabetes patients using conditional deep generative models. Integrates with CGM sensors, smart insulin pens, and mobile applications for personalized glycemic trend analysis and therapy adjustment simulations.
• Universal Concentrator (DT4) System focused on hypoglycemia prevention for insulin-dependent patients, developed with Insulcloud. Addresses root causes of hypoglycemia through AI algorithms and clinical application to improve treatment adherence and glycemic control.
• International Summer School on AI for Diabetes Management Annual one-week intensive educational program for PhD and Master's students covering CGM forecasting, automated insulin regulation, computer vision for diabetic retinopathy, LLM applications in clinical care, and bioethics. Registration at €300 per participant, featuring world-renowned faculty from institutions including Imperial College London, University of Virginia, Johns Hopkins, and Cambridge.

Quantifiable outcome

• €4,698,565.58 in total awarded research funding secured across approximately 200 funded projects
• +2 more outcomes

Named customers3 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

AI capability11 records

Feature6 records

Partnerships

Eleven partnerships are on record, tiered core and flagship.

• Hospital Dr. Josep TruetacoreStrategic or Co-development Partner · 22 November 2025The Dr. Josep Trueta University Hospital is a key clinical partner participating in the PEDAL-T1D clinical trial and other diabetes research initiatives. The hospital provides clinical expertise, patient recruitment, and medical oversight for studies combining cycling with AI-driven diabetes management research.
• School of Health and Sports (EUSES)coreStrategic or Co-development Partner · 22 November 2025EUSES (School of Health and Sports) co-organizes the PEDAL-T1D clinical trial with MICELAB, contributing sports science and health expertise to the study of glycemic responses during long-duration cycling in people with type 1 diabetes.
• IDIBGI (Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta)coreStrategic or Co-development Partner · 1 September 2024IDIBGI is a clinical research partner participating in the IRENE project (PID2023-149837OB-I00) on non-invasive vagus nerve stimulation for obesity and systemic lupus erythematosus, and the DIABETEXX project on sex-specific insulin therapies. Provides clinical research infrastructure and patient access.
• Fundació de Recerca Clínic BarcelonacoreStrategic or Co-development Partner · 1 September 2024Participates in the IRENE project on non-invasive vagus nerve stimulation alongside MICELAB, IDIBGI, and University of Cambridge. Contributes clinical research expertise in autoimmune diseases and neuromodulation therapies.
• University of CambridgecoreStrategic or Co-development Partner · 1 September 2024University of Cambridge participates in the IRENE project through its Department of Electrical and Electronic Engineering and related research groups, contributing expertise in neuromodulation and biomedical devices to the nVNS research program.
• Universitat Politècnica de ValènciacoreStrategic or Co-development Partner · 1 September 2023Collaborates on the DIABETEXX project (PID2022-137723OB-C22) investigating sex-specific insulin therapies for type 1 diabetes, contributing physiological modeling and control systems expertise alongside MICELAB and Fundació Clínic.
• DexcomflagshipStrategic or Co-development Partner · 1 January 2023Dexcom is the primary industry partner through the UdG-Dexcom Chair in Artificial Intelligence for Diabetes (Reference: TSI-100932-2023-1, €899,999.78, 2023-2026). The chair aims to integrate AI into diabetes care through interdisciplinary research, professional training, and knowledge dissemination. Dexcom contributes expertise in continuous glucose monitoring technology and co-funds the chair along with the Ministry of Digital Transformation. The partnership includes joint research projects, the PEDAL-T1D clinical trial, summer schools, and the LATAM Collaboration Network.
• SocialDiabetescoreStrategic or Co-development Partner · 1 January 2022SocialDiabetes is a digital health platform consisting of a mobile application and web platform developed with patients and doctors. MICELAB collaborates on the project 'Artificial Pancreas for Patients with Continuous Monitoring Devices and Smart Insulin Pens' (Reference: CPP2021-008659, €656,441.06, 2022-2025), developing and clinically validating a control algorithm for blood glucose control that includes correction insulin boluses and rescue carbohydrate recommendations.
• InsulcloudcoreStrategic or Co-development Partner · 1 January 2022Insulcloud provides a smart insulin pen platform with dose logging, sensors, and connectivity. MICELAB collaborates on two projects: (1) Universal Concentrator project (Reference: CPP2021-009139, €1,568,129.80, 2022-2025) focused on hypoglycemia prevention, and (2) Synulin AI project (Reference: CPP2024-011898, €875,000, 2024-2027) developing a synchronized smart insulin pen with integrated AI agent control, virtual human twin, and gamification.
• Imperial College LondoncoreStrategic or Co-development Partner · 1 September 2021Imperial College London participates in the VaNeSA project (PID2020-117171RA-I00) on non-invasive vagus nerve stimulation for autoimmune diseases, contributing expertise in biomedical engineering, control systems, and the artificial pancreas. Imperial's Center for Diabetes Technology provides research collaboration on AI-driven diabetes management.
• ACCIÓ / Government of Catalonia (TECNIO)coreOthersACCIÓ, the Government of Catalonia's agency for business competitiveness, grants the TECNIO accreditation (DOGC no. 987259) which identifies MICELAB as one of the most qualified technology developers in the Catalan R&D ecosystem. TECNIO certification validates their expertise in technology transfer, connects them to European funding opportunities, and serves as a mark of excellence for industry collaboration.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Diabeloop: French commercial company developing AI-driven closed-loop insulin delivery systems for T1D; directly comparable in product (personalized AP algorithms) and customer base (T1D patients and device partners).
• CamDiab: UK-based clinical-stage company commercializing the CamAPS FX closed-loop artificial pancreas algorithm spun out of Cambridge research — directly comparable AI/AP technology commercialized through partnerships with insulin pump OEMs.
• Beta Bionics: Developer of the iLet bionic pancreas, an automated insulin delivery system using algorithmic dosing — a direct peer in AI-driven closed-loop diabetes technology commercialization.
• Stanford Diabetes Research Center: Interdisciplinary academic center conducting diabetes research spanning AI, biomedical engineering, and clinical care — comparable as a multidisciplinary academic hub with overlapping AI/diabetes focus.
• Jaeb Center for Health Research: Non-profit coordinating large-scale T1D clinical trials (e.g., DirecNet, T1D Exchange); comparable as a research/clinical-trial infrastructure player in the diabetes technology ecosystem.
• University of Virginia Center for Diabetes Technology: Academic research center developing closed-loop artificial pancreas systems, in-silico testing, and decision-support algorithms for type 1 diabetes — directly comparable to MICELAB in mission, methods, and clinical focus.
• Imperial College London Centre for Diabetes Technology: Multidisciplinary research group working on artificial pancreas, control algorithms, and clinical diabetes technology — a direct academic peer and existing MICELAB collaborator via the UdG-Dexcom Chair ecosystem.

Broad incumbents

• Tandem Diabetes Care: Commercial insulin pump manufacturer with the t:slim X2 Control-IQ AI-driven closed-loop system; incumbent that integrates similar AI dosing algorithms into a broader commercial pumps and consumables portfolio.
• Insulet: Commercial maker of the Omnipod tubeless insulin pump, integrating algorithm partners (including former DreaMed) for closed-loop functionality — broader incumbent that consumes similar AI dosing technology.
• Medtronic Diabetes: Global medical device incumbent with the MiniMed 780G closed-loop system; broader portfolio player that competes with and potentially partners with MICELAB's algorithm and digital twin capabilities.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/micelab-udg

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MiceLab UdG